BTIG Research Cuts Outset Medical (NASDAQ:OM) Price Target to $15.00

Outset Medical (NASDAQ:OM) had its target price cut by BTIG Research from $17.00 to $15.00 in a report issued on Thursday, Marketbeat Ratings reports. They currently have a buy rating on the stock.

Other research analysts have also issued reports about the stock. Royal Bank Of Canada reissued a “sector perform” rating and issued a $7.00 target price on shares of Outset Medical in a research note on Wednesday, December 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Outset Medical in a research report on Monday, December 29th. Stifel Nicolaus lowered their price objective on Outset Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, January 7th. Finally, Wall Street Zen downgraded Outset Medical from a “hold” rating to a “sell” rating in a research note on Sunday, February 8th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Outset Medical Trading Down 10.8%

Shares of OM stock opened at $3.39 on Thursday. Outset Medical has a fifty-two week low of $3.10 and a fifty-two week high of $21.98. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.77 and a current ratio of 7.09. The stock’s fifty day moving average is $4.42 and its two-hundred day moving average is $9.37. The firm has a market capitalization of $61.54 million, a P/E ratio of -0.50 and a beta of 2.08.

Insider Activity

In other Outset Medical news, CEO Leslie Trigg sold 11,794 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total value of $60,385.28. Following the sale, the chief executive officer directly owned 107,823 shares of the company’s stock, valued at approximately $552,053.76. This trade represents a 9.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel John L. Brottem sold 9,314 shares of the company’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $5.12, for a total transaction of $47,687.68. Following the transaction, the general counsel directly owned 36,957 shares of the company’s stock, valued at approximately $189,219.84. This represents a 20.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 35,989 shares of company stock valued at $180,073 over the last quarter. Company insiders own 2.40% of the company’s stock.

Institutional Trading of Outset Medical

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Stifel Financial Corp acquired a new position in Outset Medical during the fourth quarter valued at approximately $297,000. Wells Fargo & Company MN raised its stake in shares of Outset Medical by 57.0% in the 4th quarter. Wells Fargo & Company MN now owns 18,271 shares of the company’s stock valued at $68,000 after acquiring an additional 6,632 shares during the period. HRT Financial LP acquired a new position in shares of Outset Medical during the 4th quarter valued at $58,000. Aristides Capital LLC acquired a new position in shares of Outset Medical during the 4th quarter valued at $177,000. Finally, Paradigm Capital Management Inc. NY purchased a new stake in Outset Medical during the 4th quarter worth $148,000.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.